Yeah, of course, but the idea behind writing-in contingencies on a contract is that the described deal only goes ahead if the specified parameters are met. Therefore, in your scenario, the partner entity are not liable for the proposed $30m until the specific hurdle (e.g. 2x2) is clear. My company has contingencies in just about all our supplier contracts. Basically, they are in-principle deals which only become formalised when a specified milestone is reached. It can end up benefiting both sides. In PAR's case, this could immediately re-invite optimism and lift the share-price if a CR is needed to bridge the gap, it may even assist in securing a credit-agreement / debt-funding, again to bridge the gap until the trials are green-lit because that is the trigger for up-front payment. This all feels better to me than being forced to CR while the company is in it's current circumstance of open-ended waiting time and dwindling cash position.
- Forums
- ASX - By Stock
- PAR
- Why Zilosul could be a golden goose!!
PAR
paradigm biopharmaceuticals limited..
Add to My Watchlist
0.00%
!
29.0¢

Why Zilosul could be a golden goose!!, page-81
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
29.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $112.9M |
Open | High | Low | Value | Volume |
28.5¢ | 29.5¢ | 28.5¢ | $6.777K | 23.58K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
9 | 78247 | 28.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
29.5¢ | 28231 | 6 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
8 | 75501 | 0.285 |
17 | 249947 | 0.280 |
5 | 37486 | 0.275 |
5 | 47147 | 0.270 |
1 | 11206 | 0.265 |
Price($) | Vol. | No. |
---|---|---|
0.295 | 9917 | 3 |
0.300 | 40366 | 2 |
0.305 | 152979 | 2 |
0.310 | 118515 | 5 |
0.315 | 59233 | 3 |
Last trade - 10.32am 16/06/2025 (20 minute delay) ? |
Featured News
PAR (ASX) Chart |